• Explore /
  • Poster
  • / Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study.

Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study.

Abstract Poster

Authors

null

Guillaume Cartron

CHU de Montpellier, Montpellier, France

Guillaume Cartron , Emmanuel Bachy , Herve Tilly , Nicolas Daguindau , Gian Matteo Pica , Fontanet Bijou , Christiane Mounier , Aline Clavert , Gandhi Laurent Damaj , Borhane Slama , Olivier Casasnovas , Roch Houot , Krimo Bouabdallah , David Sibon , Olivier Fitoussi , Nadine Morineau , Franck Morschhauser , Luc Xerri , Karin Tarte , Delphine Pranger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02303119

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7512)

DOI

10.1200/JCO.2022.40.16_suppl.7512

Abstract #

7512

Poster Bd #

166

Abstract Disclosures

Similar Posters

First Author: Ian W. Flinn

First Author: Kitsada Wudhikarn

First Author: Martin H. Dreyling

First Author: Lorenzo Falchi